Stay updated on Nivolumab in Untreated Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Untreated Lung Cancer Clinical Trial page.

Latest updates to the Nivolumab in Untreated Lung Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe webpage has been updated to include new results and definitions related to major pathologic response (mPR) and pathologic complete response (pCR) in lung cancer treatment, along with updated survival metrics and reporting dates. Several previous entries regarding study design and historical comparisons have been removed.SummaryDifference30%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.8%
- Check46 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference0.8%
- Check53 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.0%
- Check67 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.0%
- Check74 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference0.1%
Stay in the know with updates to Nivolumab in Untreated Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Untreated Lung Cancer Clinical Trial page.